This site is intended for Healthcare Professionals outside the US

Significant, rapid, and durable improvements in QoL1

Patients treated with JAKAVI experienced durable improvement in QoL at 3-year follow-up1

COMFORT-I: Durable improvements in global health status and QoL with JAKAVI vs placebo at 3-year follow-up1

Patients treated with JAKAVI, a JAK2 Inhibitor, experienced durable improvement in Quality of Life

Adapted from: Verstovsek S et al. Abstract handout presented at: American Society of Hematology Annual Meeting, 2013.1
Based on a prespecified exploratory endpoint.

  • At 3-year follow-up, patients treated with JAKAVI experienced durable improvements in the Global Health Status/QoL and functional domains of the EORTC QLQ-C301

JAKAVI Treatment in Clinical Practice: Managing severe MF-related fatigue

Fatigue is a debilitating symptom, present in a large majority of patients with MF, and can severely impact patient quality of life. Watch the video below to learn more from Dr Ruben Mesa about managing MF-related fatigue with JAKAVI.

Next: Overall survival benefit with JAKAVI

EORTC QLQ C30=European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; MF=myelofibrosis; QoL=quality of life.

Reference:

  1. Verstovsek S, Mesa RA, Gotlib J, et al; for the COMFORT-I investigators. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479-488.